1. Academic Validation
  2. Paracrine Action of Bone Morphogenetic Protein 3 in Pulmonary Arterial Hypertension

Paracrine Action of Bone Morphogenetic Protein 3 in Pulmonary Arterial Hypertension

  • bioRxiv. 2025 Jun 18:2025.06.13.659638. doi: 10.1101/2025.06.13.659638.
Aymen Halouani 1 Eric Mensiah 1 Zaujia Athumani 1 Michael G Katz 2 Katherine Jankowski 3 Maryam Mansoori 3 Vicki Rosen 4 Kiyotake Ishikawa 2 Lahouaria Hadri 3 Yassine Sassi 1 5 6
Affiliations

Affiliations

  • 1 Fralin Biomedical Research Institute at Virginia Tech Carilion, Roanoke, VA, USA.
  • 2 Icahn School of Medicine at Mount Sinai, New York, USA.
  • 3 Department of Pharmacological Science, Icahn School of Medicine at Mount Sinai, New York, USA.
  • 4 Department of Developmental Biology, Harvard School of Dental Medicine, Boston, MA, USA.
  • 5 Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, Virginia.
  • 6 Department of Internal Medicine, VTC School of Medicine, Roanoke, Virginia.
Abstract

Background: Despite recent advancements in the management of pulmonary arterial hypertension (PAH), the disease remains devastating, with limited survival. Although the Bone Morphogenetic Protein (BMP) signaling pathway is known to play an important role in PAH, our current understanding of this pathway remains limited.

Methods: We assessed BMP3 levels in the lungs of mice, rats, and pigs with pulmonary hypertension, and in pulmonary vascular cells from human patients with PAH. We performed in vitro studies on human pulmonary artery smooth muscle cells (hPASMCs) and human pulmonary artery endothelial cells (hPAECs) derived from healthy donors and from patients with PAH. We generated mice with global or SMC-specific deletion of BMP3. Recombinant BMP3 protein and adeno-associated viruses (AAV) were used to overexpress BMP3 in two different models of PAH in rodents. Magnetic resonance imaging, cardiac hemodynamics, morphometric, and histological measurements were performed to evaluate the effects of BMP3 on cardiac function and pulmonary vascular remodeling.

Results: BMP3 is predominantly expressed in PASMCs and is downregulated in PAH. In vitro, conditioned medium from siRNA-BMP3-transfected hPASMCs increased hPAECs migration and proliferation, while PASMC-derived BMP3 inhibited PAH-diseased PAEC dysfunction. In both global and SMC-specific BMP3-deficient mice, exposure to a model of PAH exacerbated cardiac and pulmonary vascular remodeling in middle-aged mice. An intraperitoneally injected recombinant BMP3 prevented and reversed PAH in mice. A lung-targeted overexpression of BMP3, via AAV1-BMP3, reversed pulmonary vascular remodeling and inhibited cardiac dysfunction in mice and rats. Mechanistically, BMP3 activated the BMP/Smad1,5,8 pathway, inhibited the TGF-β/SMAD2,3 pathway, and decreased the expression of cell cycle genes in hPAECs and in the lungs of BMP3-treated Animals with PAH.

Conclusions: Our findings provide evidence that BMP3 overexpression attenuates pulmonary vascular remodeling and inhibits cardiac dysfunction by restoring the balance between the TGF-β and BMP pathways through a cell-cell communication mechanism, offering a novel therapeutic pathway for PAH.

Keywords

BMP3; Endothelial Cells; Paracrine Signaling; Pulmonary Arterial Hypertension; Smooth Muscle Cells.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-10374
    99.96%, Flk-1/KDR Inhibitor